CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 30 enrolled
Drug / intervention
Humidified nasal high flow with oxygendevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03221387
NCT03221387N/ACompleted
CompareCT.gov

Feasibility of Using Daily Home HNHF-O2 During Sleep and/or Daytime in Hypercapnic COPD Patients Following Recent (&lt 12 Wks.) Hospitalization for AECOPD for 90 Days

Temple University·interventional·Posted Jul 18, 2017·Updated Jun 7, 2021

In Brief

A clinical study evaluating Humidified nasal high flow with oxygen for Pulmonary Disease, Chronic Obstructive and 2 related conditions. Completed, enrolled 30 participants across 1 site.

Detailed Summary

Humidified Nasal High-flow with Oxygen (HNHF-O2) therapy has been reported to have acute beneficial effects in patients with hypoxemic respiratory failure who have been hospitalized. The usefulness of this therapy in the outpatient setting is unproven. This pilot study will test the feasibility of using this therapy in the outpatient setting and its effects on sleep.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive, Hypercapnia, Hypoxia
CountriesUnited States
CollaboratorsFisher and Paykel Healthcare

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedJul 18, 2017
Enrollment StartSep 10, 2017
Primary CompletionDec 15, 2019
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 9.0 years ago

Interventions

Humidified nasal high flow with oxygendevice

The AIRVO 2 is for the treatment of spontaneously breathing patients who would benefit from receiving high flow warmed and humidified respiratory gases.